MFN Drug Pricing in 2026: Breaking Down GENEROUS, GLOBE, GUARD & TrumpRx

A straightforward look at five federal drug pricing initiatives, including Medicare and Medicaid rebate changes, manufacturer implications, and 2027 implementation timelines.

Regulatory Update | November 2026

The U.S. pharmaceutical pricing landscape continues to undergo significant change. Over the past year, the
Trump Administration has introduced several initiatives intended to align U.S. prescription drug prices to
prices paid in other developed nations.

While these initiatives share a common objective, they operate through different programs, have different
requirements, and follow different implementation timelines.

For pharmaceutical manufacturers, understanding which programs are active, which are mandatory, and which remain proposed is essential for evaluating potential financial and operational impacts.

Here’s a straightforward breakdown of five key initiatives and what manufacturers need to know.

At a Glance: Federal Drug Pricing Initiatives

Status as of October 26, 2026. Drug eligibility is subject to additional therapeutic-category requirements and exclusions. GLOBE’s implementation remains subject to legal developments.

 The following sections provide additional details on each initiative, including applicability, potential
implications for manufacturers, and implementation timelines.

1. Most-Favored-Nation (MFN) Pricing

Status: Active federal policy; implementation underway

What is it?

Most-Favored-Nation (MFN) pricing is a federal policy intended to align U.S. prescription drug prices with
lower prices paid in other developed countries.

Established through Executive Order 14273 in April 2025 and expanded through Executive Order 14297 in May 2025, the policy has led to voluntary manufacturer agreements and several new federal pricing initiatives.

What does it mean for manufacturers NOW?

• Voluntary MFN agreements may include commitments involving Medicaid pricing, newly launched
  medications, and direct-to-consumer sales.
• Manufacturers should evaluate potential impacts on U.S. and international pricing strategies,
  contracting, and future product launches.

What’s next?

MFN serves as the broader policy framework supporting GENEROUS, GLOBE, GUARD, and TrumpRx. While
additional requirements may emerge, MFN is not a single, universal pricing mandate applicable to every
manufacturer or product.

2. GENEROUS Model: Medicaid

Status: Active; voluntary participation

What is it?

GENEROUS stands for GENErating cost Reductions fOr U.S. Medicaid.

The model allows participating manufacturers to offer Medicaid lower net drug prices based on prices in
selected other countries.

Unlike traditional Medicaid supplemental rebate agreements negotiated with individual states, CMS centrally
negotiates the pricing framework and coverage requirements with manufacturers, establishing more consistent terms across participating states, as outlined in the CMS GENEROUS Model overview.
What does it mean for manufacturers NOW?

• Additional Rebates: Manufacturers continue paying their regular Medicaid statutory rebates, including
  applicable inflation rebates. Additional supplemental rebates are then calculated to achieve an
  internationally benchmarked Guaranteed Net Unit Price (GNUP).
• Rebate Calculation: As detailed in the CMS Manufacturer Request for Applications, supplemental
  rebates are calculated using the formula: Supplemental Rebate = WAC − (GNUP + Medicaid Unit Rebate
  Amount). States invoice manufacturers quarterly.
• Potential Market Access Benefits: In exchange for lower net prices, manufacturers may benefit from
  more consistent Medicaid coverage requirements, potentially increased utilization, and reduced state-
  by-state negotiations. However, increased utilization is not guaranteed and must be weighed against
  additional rebate costs.
• Government Pricing Impact: GENEROUS supplemental rebates are excluded from AMP and Medicaid
  Best Price calculations under existing CMS-authorized supplemental rebate rules (42 CFR § 447.504
  and 42 CFR § 447.505). CMS also confirms no impact on 340B ceiling prices. Manufacturers should
  evaluate any implications for other Government Pricing calculations.

CMS announced that all 50 states, Washington, D.C., and Puerto Rico applied to participate in the model.

What’s next?

The model launched in January 2026 and is scheduled to operate through December 2030.
Manufacturers should evaluate the potential financial benefits of increased market access against additional
rebate obligations, while preparing for international pricing data requirements, quarterly rebate processing,
and ongoing compliance.

3. GLOBE Model: Medicare Part B

Status: Final rule effective November 30, 2026; mandatory model launching January 1, 2027; legal challenge pending

What is it?

GLOBE stands for Global Benchmark for Efficient Drug Pricing.

The model targets certain higher-cost medications covered under Medicare Part B, generally drugs
administered in a physician’s office or other healthcare setting.

Under GLOBE, manufacturers may owe additional Medicare rebates when drug prices exceed an international
pricing benchmark.

Which drugs are subject to GLOBE?

As outlined in the CMS GLOBE Model overview, the model generally targets drugs that meet the following
criteria:

• Drug Type: Single-source drugs and sole-source biological products covered under Medicare Part B.
• Therapeutic Categories: Selected drugs within oncology, rheumatology, immunology, ophthalmology,
  and endocrinology.
• Spending Threshold: Drugs with more than $100 million in annual Original Medicare Part B spending
  over a qualifying 12-month period.
• Exclusions: Certain products are excluded, including biosimilars and their reference biologics once a
  biosimilar enters the U.S. market, orphan-only drugs, plasma-derived products, and certain cell and
  gene therapies.

These criteria apply at the product level, regardless of manufacturer size. CMS will publish and update the list
of qualifying drugs quarterly.

What does it mean for manufacturers NOW?

• Mandatory Participation: Unlike GENEROUS, GLOBE is mandatory for manufacturers with qualifying
  products that are not otherwise excluded.
• Additional Rebates: Manufacturers may face increased Medicare Part B rebate obligations calculated
  using international pricing benchmarks.
• International Pricing Data: Manufacturers can voluntarily submit international net pricing data, which
  CMS may use in determining rebate calculations.
• Financial and Operational Implications: Manufacturers should evaluate potential impacts on rebate
  liability, gross-to-net forecasts, international pricing strategies, and reporting processes.

What’s next?

GLOBE is scheduled to launch January 1, 2027, with reduced patient coinsurance beginning April 1, 2027. The model will initially apply to geographic areas representing approximately 25% of eligible Original Medicare
beneficiaries.

Per the CMS GLOBE Model FAQs, the first voluntary international net pricing data submission window is
January 1–30, 2027, covering fourth-quarter 2026 sales.

Important Legal Development: On October 7, 2026, the Pharmaceutical Research and Manufacturers of
America (PhRMA) filed a lawsuit challenging the GLOBE final rule. While the challenge introduces uncertainty,
the lawsuit does not automatically suspend implementation.

Manufacturers with potentially qualifying products should begin preparing for the model while monitoring the
legal proceedings and additional CMS guidance, including the final rule published October 2, 2026.

4. GUARD Model: Medicare Part D

Status: Proposed rule; mandatory if finalized; January 1, 2027 proposed launch

What is it?

GUARD stands for Guarding U.S. Medicare Against Rising Drug Costs.

Similar to GLOBE, GUARD would establish internationally benchmarked rebate calculations, but for certain
drugs covered under Medicare Part D, generally medications dispensed through pharmacies.

The model would modify how Medicare Part D inflation rebates are calculated, potentially increasing
manufacturer rebate obligations when U.S. net prices exceed international benchmarks.

Which drugs would be subject to GUARD?

According to the CMS GUARD Model proposal, qualifying drugs would generally include:

• Drug Type: Certain single-source drugs and biological products subject to the Medicare Part D Inflation
  Rebate Program.
• Therapeutic Categories: Selected drugs across multiple categories, including oncology, diabetes,
  cardiovascular, respiratory, neurological, and immunological treatments.
• Spending Threshold: Drugs exceeding a proposed $69 million annual Medicare Part D gross spending
  threshold, measured at the drug application level.
• Exclusions: Certain products, including generics, biosimilars, and drugs subject to an applicable
  Medicare negotiated Maximum Fair Price (MFP).

What does it mean for manufacturers NOW?

• Proposed Mandatory Participation: If finalized, manufacturers with qualifying products would be
  required to participate.
• Rebate Calculation: GUARD would use an international pricing benchmark to calculate an alternative
  Part D rebate amount, potentially replacing the standard inflation rebate calculation when the GUARD
  amount is higher.
• Pricing Data: Manufacturers could voluntarily submit international net pricing information to support
  an alternative benchmark calculation.
• Financial Implications: Manufacturers should evaluate potential additional Part D rebate liability,
  including impacts on gross-to-net forecasts, pricing strategies, and reporting processes.

The proposed methodology is detailed in the Federal Register GUARD Proposed Rule. Because the rule has not been finalized, manufacturers should treat these calculations as potential future requirements.

What’s next?

CMS has proposed a January 1, 2027 launch, with the model operating through December 2031 and rebate
invoicing and reconciliation continuing into 2033.

As January 1, 2027 is quickly approaching and, under the Congressional Review Act, a major rule generally
cannot take effect until 60 days following Publication in the Federal Register or Congress receiving the
required rule report, the likelihood of seeing this rule go into effect on January 1, 2027 may be dropping.
Based on CMS statutorily mandated deadlines, final regulations must be published within a three-year
window, thereby requiring action by December 23, 2028 for the rule to move forward.

If approved, the proposal would initially apply to approximately 25% of Medicare Part D beneficiaries in
randomly selected geographic areas.

Manufacturers should monitor publication of a final rule for confirmation of applicable products, rebate
methodologies, reporting obligations, and implementation dates.

5. TrumpRx: Direct-to-Consumer Drug Pricing

Status: Active; voluntary participation; launched February 5, 2026

What is it?

TrumpRx.gov connects patients with discounted prescription medications through manufacturer-supported direct-to-consumer programs and pharmacy coupons. Participation is voluntary, and TrumpRx is not a mandatory government rebate program.

What does it mean for manufacturers NOW?

• Manufacturer Incentives: Participation may be part of broader MFN agreements offering tariff relief and greater regulatory certainty. Qualifying manufacturers with MFN pricing and U.S. manufacturing agreements may receive pharmaceutical tariff exemptions.
• Government Pricing Impact: Direct manufacturer-to-patient sales are excluded from AMP and Medicaid Best Price calculations (42 CFR § 447.504 and 42 CFR § 447.505). However, pharmacy-based discounts may receive different treatment, and ASP may be affected for applicable Part B products.

What’s next?

Since its February 2026 launch, TrumpRx has continued expanding. There is no mandatory participation deadline.

What Should Pharmaceutical Manufacturers Be Doing Now?

As international pricing benchmarks become more prominent in U.S. drug pricing policy, manufacturers should focus on three priorities:

1. Assess Potential Exposure. Identify products that may qualify for GLOBE or GUARD based on therapeutic categories, Medicare spending thresholds, and exclusions.
2. Evaluate Pricing and Reporting Readiness. Review international pricing data availability, potential rebate implications, and Government Pricing considerations. Financial impacts may be difficult to quantify until additional implementation details are available.
3. Monitor Regulatory Developments. Track GLOBE’s January 2027 implementation, ongoing litigation, and additional CMS guidance, along with GUARD’s proposed requirements and timeline.

Looking Ahead

The federal government’s increasing reliance on international drug price comparisons represents an important shift in U.S. pharmaceutical pricing policy.

While not every initiative will apply to every manufacturer, these developments could have meaningful implications for Government Pricing, rebate obligations, gross-to-net forecasting, and broader commercial strategies.

As these policies evolve, manufacturers benefit from having an experienced partner they can turn to for
guidance and perspective on potential business implications.

At Prescription Analytics, Inc., we go beyond fully managed Government Pricing and Rebate Processing to
provide ongoing regulatory guidance and collaborative support. If your organization would benefit from a
knowledgeable partner to discuss these developments and their potential impact, we welcome the
opportunity to connect.

This article reflects publicly available information as of October 26, 2026, and is intended for educational purposes. Regulatory requirements and implementation timelines may change. Manufacturers should evaluate company-specific implications with qualified legal and Government Pricing advisors.